Daré Bioscience inks royalty deal with XOMA: The company received $22 million, which is expected to help progress a pair of women’s health therapies through Phase 3. Dare’s stock $DARE was up about 28% after announcing the agreement. — Jaimy Lee
WELLESLEY, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc. (the “Company” or “Qlaris”), a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, today announced results from QC-201, a first-in-human, Phase 2 clinical trial of QLS-101, the Company’s investigational therapy for lowering intraocular pressure (IOP) in the treatment of glaucoma. Study findings demonstrated a favorable safety and tolerability profile for QLS-101, including no evidence of hyperemia (eye redness), as well as a positive efficacy signal, in patients with primary open-angle glaucoma (POAG) or ocular hypertension.